Temporal regression of myocyte hypertrophy in hypertensive, heart failure-prone rats treated with an AT1-receptor antagonist.

Abstract

BACKGROUND:

A recent study showed reverse remodeling of left ventricular myocyte shape when the type 1 angiotensin II (AT1)-receptor antagonist L-158,809 was administered to spontaneously hypertensive heart failure (SHHF) rats 4 months before the onset of failure. The aim of this study was to characterize temporally early treatment-induced reverse remodeling at the organ and cellular level by echocardiography and morphometry of isolated left ventricular myocytes.

METHODS AND RESULTS:

L-158,809 was administered to 9-month-old SHHF rats. Blood pressure normalized shortly after initiation of treatment. Isolated myocytes were collected in terminal experiments to assess cell remodeling. L-158,809 reduced myocyte volume and cross-sectional area significantly after 1 week of treatment with maximal regression of hypertrophy, including reduced cell length, obtained by 4 weeks. Reduced wall thickness was clearly detectable by echocardiography within 4 weeks after initiation of treatment.

CONCLUSIONS:

Regression of left ventricular myocyte hypertrophy occurred rapidly after initiation of AT1-blocker therapy in SHHF rats and was completed within 1 month. Regression of myocyte hypertrophy was associated with reduced wall thickness, which was detected consistently by echocardiography within 1 month after initiation of treatment.

• Authors: Tetsutaro Tamura, Suleman Said, Susan M K Andersen, Sylvia A McCune, Seibu Mochizuki, A Martin Gerdes
• Journal: Journal of cardiac failure (J Card Fail) Vol. 8 Issue 1 Pg. 43-7 (Feb 2002) ISSN: 1071-9164 [Print] United States
• PMID: 11862582 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Imidazoles
• Tetrazoles
• Angiotensin II
• L 158809

Topics

• Angiotensin II (antagonists & inhibitors)
• Animals
• Antihypertensive Agents (therapeutic use)
• Female
• Hypertension (drug therapy)
• Hypertrophy, Left Ventricular (drug therapy, pathology)
• Imidazoles (therapeutic use)
• Myocardium (pathology)
• Rats
• Rats, Inbred SHR
• Tetrazoles (therapeutic use)
• Time Factors